Subtype
Female Reproductive System Neoplasm
CI-CAN-00000885Explore in graph →
Non-malignant1,630 active trials11 approved drugs139 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000885Explore in graph →
Clinical trials
7,171 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03203993 | China Ovarian Cancer BRCA Testing Study(CRONUS) | terminated | — | 29 | AstraZenecaINDUSTRY | 2 | Oct 14, 2020 | clinicaltrials |
| NCT02476955 | Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole | terminated | Phase 1 | 41 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)INDUSTRY | 1 |
| Sep 30, 2020 |
| clinicaltrials |
| NCT01690468 | PTX-200 and Carboplatin in Ovarian Cancer | terminated | Phase 1 / Phase 2 | 15 | Prescient Therapeutics, Ltd.INDUSTRY | 1 | Sep 24, 2020 | clinicaltrials |
| NCT03957096 | A Safety Study of SGN-CD47M in Patients With Solid Tumors | terminated | Phase 1 | 16 | Seagen Inc.INDUSTRY | 1 | Sep 17, 2020 | clinicaltrials |
| NCT01535157 | Fenretinide/LXS Oral Powder Plus Ketoconazole in Recurrent Ovarian Cancer | terminated | Phase 1 / Phase 2 | 12 | South Plains Oncology ConsortiumNETWORK | 1 | Aug 27, 2020 | clinicaltrials |
| NCT01939028 | Lymph Node Mapping in Patients With Newly Diagnosed Endometrial Cancer Undergoing Surgery | terminated | N/A | 58 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 27, 2020 | clinicaltrials |
| NCT02346955 | Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001) | terminated | Phase 1 | 27 | Famewave Ltd.INDUSTRY | 2 | Aug 27, 2020 | clinicaltrials |
| NCT02045433 | Stereotactic Body Radiation Therapy (SABR) for Definitive Treatment of Locally Advanced Cervical Cancer | terminated | Phase 2 | 16 | University of Texas Southwestern Medical CenterOTHER | 1 | Aug 21, 2020 | clinicaltrials |
| NCT02326844 | BMN 673 (Talazoparib), an Oral PARP Inhibitor, in People With Deleterious BRCA1/2 Mutation-Associated Ovarian Cancer Who Have Had Prior PARP Inhibitor Treatment | terminated | Phase 2 | 3 | National Cancer Institute (NCI)NIH | 1 | Aug 18, 2020 | clinicaltrials |
| NCT01280045 | Influence of Aromatase Inhibitors and GnRH Analogs to Treat Uterine Leiomyoma by Vaginal Hysterectomy | terminated | N/A | 5 | University of Sao PauloOTHER | 0 | Aug 13, 2020 | clinicaltrials |
| NCT01738724 | Study of the Efficacy of Dienogest in the Treatment of Uterine Leiomyomas When Compared to Desogestrel and Goserelin | terminated | Phase 4 | 14 | University of Sao PauloOTHER | 0 | Aug 13, 2020 | clinicaltrials |
| NCT03587129 | Clinical Study of Apatinib in the Treatment of Platinum Resistant Recurrent Ovarian Cancer | terminated | Phase 2 | 1 | First Affiliated Hospital of Harbin Medical UniversityOTHER | 1 | Aug 5, 2020 | clinicaltrials |
| NCT01249443 | Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection | terminated | Phase 1 | 17 | AIDS Malignancy ConsortiumNETWORK | 1 | Jul 29, 2020 | clinicaltrials |
| NCT02718417 | Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100) | terminated | Phase 3 | 998 | PfizerINDUSTRY | 25 | Jul 14, 2020 | clinicaltrials |
| NCT02387125 | Phase 1b Safety Study of CMB305 in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1 | terminated | Phase 1 | 79 | Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 1 | Jul 1, 2020 | clinicaltrials |
| NCT02317302 | FDG Tumor Heterogeneity During Chemoradiation as a Predictor of Response in Patients With Cervical Cancer | terminated | Phase 1 | 48 | Washington University School of MedicineOTHER | 1 | Jun 11, 2020 | clinicaltrials |
| NCT03318107 | Ultrasound and Photoacoustic Imaging for Cervical Cancer | terminated | N/A | 2 | Washington University School of MedicineOTHER | 1 | May 29, 2020 | clinicaltrials |
| NCT02441140 | Detection of Tumor Associated Cell-free DNA in Peritoneal Fluid Obtained by Culdocentesis | terminated | N/A | 5 | Dana-Farber Cancer InstituteOTHER | 1 | May 4, 2020 | clinicaltrials |
| NCT01533207 | Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery | terminated | Phase 3 | 38 | Gynecologic Oncology GroupNETWORK | 8 | Apr 28, 2020 | clinicaltrials |
| NCT01312376 | Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer | terminated | Phase 1 | 18 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Apr 24, 2020 | clinicaltrials |
| NCT02452775 | Autologous OC-L Vaccine and Ovarian Cancer | terminated | Phase 1 | 3 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Apr 24, 2020 | clinicaltrials |
| NCT04132349 | Ulipristal Acetate in Symptomatic Uterine Fibroid | terminated | Phase 4 | 25 | Mỹ Đức HospitalOTHER | 1 | Apr 13, 2020 | clinicaltrials |
| NCT03286062 | VM110 in Detection of Microscopic Tumors: A Phase I Study | terminated | Phase 1 | 1 | Fox Chase Cancer CenterOTHER | 1 | Apr 7, 2020 | clinicaltrials |
| NCT02769546 | Physician-Patient Communication and Expectations Regarding Ovarian Cancer Prognosis | terminated | — | 50 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Apr 2, 2020 | clinicaltrials |
| NCT01847677 | Neoadjuvant Therapy in Advanced Ovarian Cancer With Avastin(NOVA) | terminated | Phase 2 | 71 | Grupo Español de Investigación en Cáncer de OvarioOTHER | 1 | Apr 1, 2020 | clinicaltrials |
| NCT02540551 | Sentinel Node Detection in Ovarian Cancer(SONAR-2) | terminated | Phase 1 | 11 | Maastricht University Medical CenterOTHER | 1 | Mar 24, 2020 | clinicaltrials |
| NCT02665962 | Evaluating the Effect of Perioperative Caloric Restriction Program on Perioperative Outcomes in Patients With Obesity and Endometrial Cancer | terminated | N/A | 8 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Mar 10, 2020 | clinicaltrials |
| NCT02351089 | Probiotics in Radiation-treated Gynecologic Cancer(ProRad) | terminated | N/A | 97 | Probi ABINDUSTRY | 1 | Mar 5, 2020 | clinicaltrials |
| NCT02452424 | A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors | terminated | Phase 1 / Phase 2 | 78 | Daiichi SankyoINDUSTRY | 1 | Mar 5, 2020 | clinicaltrials |
| NCT01392352 | HYPAZ: Hypertension Induced by Pazopanib(HYPAZ) | terminated | Phase 2 | 31 | Cambridge University Hospitals NHS Foundation TrustOTHER | 1 | Feb 13, 2020 | clinicaltrials |
| NCT02576665 | A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6) | terminated | Phase 1 | 21 | Tocagen Inc.INDUSTRY | 1 | Feb 7, 2020 | clinicaltrials |
| NCT03466034 | The Role of Hypoxia as a Selective Pressure for TP53 Mutations | terminated | — | 5 | Institute of Cancer Research, United KingdomOTHER | 1 | Jan 29, 2020 | clinicaltrials |
| NCT03852979 | Neo-Adjuvant Chemotherapy and Conservative Surgery in Cervical Cancer to Preserve Fertility(NEOCON-F) | terminated | Phase 2 | 1 | The Netherlands Cancer InstituteOTHER | 1 | Jan 10, 2020 | clinicaltrials |
| NCT00394602 | Chemoradiation-Induced Nausea and Emesis: Quality of Life | terminated | — | 207 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 2, 2020 | clinicaltrials |
| NCT00519272 | A Prospective Study Examining the Barriers to Care for Harris County Cervical Cancer Patients | terminated | — | 200 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 2, 2020 | clinicaltrials |
| NCT01413451 | Amatuximab for High Mesothelin Cancers | terminated | Early Phase 1 | 7 | National Cancer Institute (NCI)NIH | 1 | Dec 17, 2019 | clinicaltrials |
| NCT03300843 | Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients Against Defined Mutated Neoantigens Expressed by the Autologous Cancer | terminated | Phase 2 | 1 | National Cancer Institute (NCI)NIH | 1 | Dec 13, 2019 | clinicaltrials |
| NCT01374685 | Family Communication of Hereditary Breast and Ovarian Cancer Risk Among African Americans | terminated | — | 8 | National Human Genome Research Institute (NHGRI)NIH | 1 | Dec 3, 2019 | clinicaltrials |
| NCT00924066 | Ixabepilone to Treat Cervical Cancer | terminated | Phase 2 | 41 | National Cancer Institute (NCI)NIH | 1 | Nov 21, 2019 | clinicaltrials |
| NCT00204997 | Preservation of Ovarian Function Via LOT in Squamous Cell Carcinoma of the Cervix | terminated | N/A | 10 | University of Wisconsin, MadisonOTHER | 1 | Nov 15, 2019 | clinicaltrials |
| NCT00651716 | T Cells in Predicting Acute Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant | terminated | — | 150 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Nov 15, 2019 | clinicaltrials |
| NCT02661815 | A Phase 1b Study of Paclitaxel And Ricolinostat For The Treatment Of Gynecological Cancer | terminated | Phase 1 | 6 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 8, 2019 | clinicaltrials |
| NCT00407407 | ABI-007 With Carboplatin as First-Line Therapy in Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma | terminated | Phase 1 | 6 | CelgeneINDUSTRY | 1 | Oct 18, 2019 | clinicaltrials |
| NCT01583686 | CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer | terminated | Phase 1 / Phase 2 | 15 | National Cancer Institute (NCI)NIH | 1 | Oct 14, 2019 | clinicaltrials |
| NCT02566811 | Selective Targeting of Adjuvant Therapy for Endometrial Cancer (STATEC)(STATEC) | terminated | N/A | 49 | University College, LondonOTHER | 1 | Sep 30, 2019 | clinicaltrials |
| NCT04105465 | Study to Evaluate the Role of PlasmaJet in Patients Undergoing Groin Node Dissection for Vulval Cancer | terminated | N/A | 21 | Royal Surrey County Hospital NHS Foundation TrustOTHER | 1 | Sep 27, 2019 | clinicaltrials |
| NCT02711345 | A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers. | terminated | Phase 1 | 65 | Novartis PharmaceuticalsINDUSTRY | 6 | Sep 19, 2019 | clinicaltrials |
| NCT03427073 | A Phase I Dose-escalation Study of Subcutaneous ALM201 in Patients With Advanced Ovarian Cancer and Other Solid Tumours | terminated | Phase 1 | 20 | Almac DiscoveryINDUSTRY | 1 | Sep 11, 2019 | clinicaltrials |
| NCT01834703 | Uterine Artery Embolization(UAE) Versus High-Intensity-Focused-Ultrasound(HIFU) for Treatment of Uterine Fibroids | terminated | N/A | 85 | Chinese University of Hong KongOTHER | 1 | Aug 30, 2019 | clinicaltrials |
| NCT02012192 | GANNET53: Ganetespib in Metastatic, p53-mutant, Platinum-resistant Ovarian Cancer | terminated | Phase 1 / Phase 2 | 133 | Medical University InnsbruckOTHER | 4 | Aug 13, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Oct 14, 2020source: clinicaltrials